A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of VAY736 in Autoimmune Hepatitis

Trial Profile

A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of VAY736 in Autoimmune Hepatitis

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 10 Aug 2018

At a glance

  • Drugs Ianalumab (Primary)
  • Indications Autoimmune hepatitis
  • Focus Therapeutic Use
  • Acronyms AMBER
  • Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
  • Most Recent Events

    • 09 May 2018 Status changed from not yet recruiting to recruiting.
    • 14 Nov 2017 Planned End Date changed from 31 Dec 2020 to 30 Dec 2020.
    • 14 Nov 2017 Planned primary completion date changed from 31 Dec 2020 to 30 Dec 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top